Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies

Blood

Volumn 117, Issue 21, 2011, Pages 5573-5581

  Korde, Neha ^a,b   Kristinsson, Sigurdur Y ^c   Landgren, Ola ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CELECOXIB; CREATININE; CURCUMIN; DEXAMETHASONE; FLUORODEOXYGLUCOSE; GREEN TEA EXTRACT; HEMOGLOBIN; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IPH 2101; LENALIDOMIDE; M PROTEIN; MELPHALAN; MICRORNA; MONOCLONAL ANTIBODY; OMEGA 3 FATTY ACID; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANGIOGENESIS; CALCIUM BLOOD LEVEL; CELL ACTIVATION; CELL POPULATION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MOLECULAR IMAGING; MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; OSTEOPENIA; PLASMA CELL; PLASMA CELL DYSCRASIA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SMOLDERING MULTILPLE MYELOMA; SMOLDERING MULTIPLE MYELOMA; STATISTICAL MODEL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79957585619     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-270140     Document Type: Review

References (66)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-1369.
3. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582-2590. (Pubitemid 46961003)
4. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904-906. (Pubitemid 43156286)
5. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82(12):1468-1473. (Pubitemid 350211693)
6. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood. 2009;113(25):6386-6391.
7. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114(4):785-790.
8. Kristinsson SY, Goldin LR, Bjorkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immunerelated factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94(11):1581-1589.
9. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-5417.
10. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22):5418-5422.
11. Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211-231.
12. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64(5):814-826. (Pubitemid 8328130)
13. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85(10):945-948.
14. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569. (Pubitemid 34438817)
15. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol. 2003;30(2):169-171. (Pubitemid 36506303)
16. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721-1728.
17. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
18. Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127.
19. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817. (Pubitemid 41076419)
20. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785-789.
21. Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7): 2586-2592. (Pubitemid 47523182)
22. Bianchi G, Kyle RA, Colby CL, et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116(12):2019-2025, quiz 2197.
23. Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28(9):1606-1610.
24. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-2567. (Pubitemid 37193596)
25. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17(2):427-436. (Pubitemid 36266921)
26. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12(6):960-969. (Pubitemid 28287221)
27. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer. 2003;38(3):234-239. (Pubitemid 37259640)
28. Saez B, Martin-Subero JI, Guillen-Grima F, et al. Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes. Leukemia. 2004;18(3):654-657. (Pubitemid 38425887)
29. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
30. Chiecchio L, Dagrada GP, Ibrahim AH, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica. 2009;94(12):1708-1713.
31. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558. (Pubitemid 38235629)
32. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105(1):317-323. (Pubitemid 40053099)
33. Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22(12):2280-2284.
34. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180. (Pubitemid 351163163)
35. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692-1700. (Pubitemid 46239604)
36. Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica. 2009;94(7):1024-1028.
37. Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA. 2010;304(21):2397-2404.
38. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):571-596. (Pubitemid 350215376)
39. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20(9):1610-1617. (Pubitemid 44264105)
40. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130. (Pubitemid 47199123)
41. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1-12. (Pubitemid 46096921)
42. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008;105(35):12885-12890.
43. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia. 2009;23(9):1545-1556.
44. Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases: experimental observations. Clin Radiol. 1967;18(2):158-162.
45. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272-278. (Pubitemid 47618648)
46. Asosingh K, De Raeve H, Menu E, et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood. 2004;103(8):3131-3137. (Pubitemid 38451691)
47. Hillengass J, Zechmann C, Bauerle T, et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res. 2009;15(9):3118-3125.
48. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I-a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993;50(2):95-102. (Pubitemid 23061274)
49. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood. 2008;112(8):3122-3125.
50. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7): 1588-1595.
51. Mateos MV, Lopez-Corral L, Hernandez MT, et al, eds. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22): Abstract 614.
52. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-239. (Pubitemid 351250526)
53. Attal M, Lauwert VC, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02. Presented at: American Society of Hematology 52nd Annual Meeting; December 6, 2010;Orlando, FL.
54. Waxman AJ, Kuehl WM, Balakumaran A, Weiss B, Landgren O. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk. 2010;10(4):248-257.
55. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-493. (Pubitemid 40293498)
56. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15(8):1274-1276. (Pubitemid 32776453)
57. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114-122.
58. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res. 2009;15(18):5917-5922.
59. Kalaycio ME. Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma. Bethesda, MD: US National Institutes of Health. http://clinical trials. gov/ct2/show/NCT00099047?term= Smoldering+OR+Indolent&cond=Multiple+Myeloma&rank=5. Accessed September 21, 2009.
60. Mateos MV, San Miguel J, Blade J, Lahuerta JJ. QUIREDEX: revlimid (lenalidomide) and dexamethasone (ReDex) treatment versus observation in patients with smoldering multiple myeloma with high risk of progression. Bethesda, MD: US National Institutes of Health; 2007. http://clinicaltrials.gov/ ct2/show/NCT00480363?term=Smoldering+OR+Indolent&cond=Multiple+Myeloma& rank=3. Accessed September 21, 2009.
61. Ballester OF. Omega 3 supplementation for the prevention of disease progression in early stage chronic lymphocytic leukemia (ES-CLL), monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Bethesda, MD: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/NCT00899353?term=Smoldering+OR+Indolent& cond=Multiple+Myeloma&rank=7. Accessed September 21, 2009.
62. Zonder JA, Shannon K. Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. Bethesda, MD: US National Institutes of Health; 2009. http://clinicaltrials.gov/ct2/show/NCT00942422?term=Smoldering+OR+Indolent& cond=Multiple+Myeloma&rank=6.Accessed September 21, 2009.
63. ClinicalTrialsDatabase. Lenalidomide or observation in treating patients with asymptomatic highrisk smoldering multiple myeloma; 2010. http://clinicaltrials.gov/ct2/show/NCT01169337?term=smoldering+myeloma&rank= 6. Accessed November 21, 2010.
64. ClinicalTrialsDatabase. A phase II trial of IPH2101 (anti-KIR) in smoldering multiple myeloma (SMM); 2010. http://clinicaltrials.gov. Accessed November 21, 2010.
65. Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leuk Lymphoma. 2010;51(12):2159-2170.
66. Balakumaran A, Robey PG, Fedarko N, Landgren O. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Exp Rev Mol Diagn. 2010;10(4):465-480.